本帖最后由 橙色雨丝 于 2015-3-3 07:56 编辑
对于中晚期的惰性淋巴瘤,特别是滤泡性淋巴瘤,由于其不可治愈性,长期以来对于无治疗指征的患者专家们倾向于建议采用观察等待的策略。在美罗华出现后,这个策略开始受到质疑,目前已经成为一个存在争议的问题。近日,来自丹麦的一项研究似乎证明,即使在美罗华时代,观察等待依然是可行的。
A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. 一项以人群为基础的晚期滤泡性淋巴瘤采用观察等待策略的预后研究
El-Galaly TC1, Bilgrau AE, de NullyBrown P, Mylam KJ, Ahmad SA, Pedersen LM, Gang AO, Bentzen HH, Juul MB, Bergmann OJ, Pedersen RS, Nielsen BJ, Johnsen HE, Dybkaer K, Bøgsted M, Hutchings M.
Department of Haematology, AalborgUniversity Hospital, Aalborg, Denmark; Department of Clinical Medicine, AalborgUniversity, Aalborg, Denmark; Clinical Cancer Research Centre, AalborgUniversity Hospital, Aalborg, Denmark.
Abstract摘要
Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular lymphoma (FL), but single-agent rituximab is an alternative for these patients. In this nationwide study we describe the outcome of patients selected for WAW. 观察等待是无症状的晚期滤泡性淋巴瘤常用的策略,但是对于这些患者来说美罗华单药治疗也是一个选项。在这项全国范围内的研究中,我们报告了选择观察等待的患者的转归。
A cohort of 286 out of 849 (34%) stage III-IVA FL patients seen between 2000 and 2011, were managed expectantly and included. The 5-year progression-free survival (PFS) was 35% [95% confidence interval (CI) 29-42]. The 10-year overall survival (OS) was 65% (95%CI 54-78),and the cumulative risk of dying from lymphoma within 10 years of diagnosis was 13% (95%CI 7-20). 在2000年到2011年间,在849例III-IV期滤泡性淋巴瘤患者中一共有286例(34%)被纳入这项研究并采用了观察等待的策略。5年的无进展生存率(PFS)是35%(95%CI 29-42)。10年的总生存率是65%(95% CI 54-78)。在确诊后10年累计死于淋巴瘤的风险是13%(95%CI 7-20)。
Elevated lactate dehydrogenase and >four nodal regions involved were associated with a higher risk of lymphoma treatment and death from lymphoma. The WAW patients and a matched backgroundpopulation had similar OS during the first 50 months after diagnosis(P = 0·7), but WAW patients had increased risk of death after 50 months (P < 0·001). LDH高于正常值和受累淋巴结区超过4个与淋巴瘤治疗与死亡风险相关。观察等待的患者在确诊后的前50个月内与相对照的背景人群有相似的总生存率(P<0.7),但是在50个月后死亡风险升高(P<0.001)。
The estimated loss of residual life after10 years was 6·8 months. The 10-year cumulative risk of histological transformation was 22% (95%CI 15-29) and the 3-year OS after transformation was 71% (95%CI 58-87%). In conclusion, advanced stage FL managed by WAW had a favourable outcome and abandoning this strategy could lead to overtreatment insome patients. 在10年后预计的剩余寿命损失是6.8个月。10年累计发生组织学转变的累计风险为22%(95% CI 15-29),在发生转化后3年的总生存率是71%(95% CI 58-87%)。由此得出的结论是,采用观察等待策略的晚期滤泡性淋巴瘤患者预后较好,放弃这个策略可能会使一些患者过度治疗。
|